GE HealthCare
NASDAQ: GEHC
Stock price
73.79 USD
(+0%) TODAY
Financial Performance
5Y price score: 30
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 23%
US$ Per
Share
By default your notes are visible only to you.
58.7
52-week range
89.7
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
2.6 %
Dividend Yield TTM
0.2 %
Market cap $
$ 33,330
Price / Earnings TTM
21.4
Price / Book TTM
3
PEG TTM
4.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(1.9) %
23.6 %
23 %
Free cash flow per share growth
(3.1) %
4.2 %
-
Earnings per share growth
4.8 %
3.2 %
-
Founded: 1,994
Employees: 53,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 29, 2026)
1) Strong Orders and Backlog Growth - Orders increased by 11% year-over-year, with a record backlog of $23.9 billion, up $2.6 billion YoY. - Book-to-bill ratio stood at 1.15x, indicating strong demand across all segments. - The growth was broad-based, with significant contributions from ultrasound, MR, CT, and patient monitoring.
2) Financial Performance Highlights - Revenue for Q2 2026 was $5.3 billion, reflecting 3.5% organic growth YoY. - Product revenues grew by 4.7%, while service revenues saw a 7.7% increase. - Adjusted EBIT was $750 million, with an adjusted EBIT margin of 14.2%, down 40 basis points YoY. - Adjusted EPS reached $1.13, up 6.6% YoY, benefiting from tariff refunds and a lower tax rate.
3) Challenges in Patient Care Solutions - Patient Care Solutions (PCS) experienced a revenue decline of 13.5%, attributed to operational fulfillment challenges and supply chain issues. - Despite these challenges, PCS saw strong orders growth in monitoring, indicating potential for recovery. - A strategic review of PCS is underway to explore options for maximizing long-term growth, including potential sale or restructuring.
4) Innovation and Product Pipeline - The company is focused on launching new AI-enabled products, with several innovations expected to drive growth in the second half of 2026 and beyond. - Photonova Spectra, a photon-counting CT platform, is anticipated to enhance market opportunities post CE marking. - The pharmaceutical diagnostics segment reported strong growth of 14.6%, driven by increased adoption of disease-specific tracers and the Flyrcado ramp.
5) Guidance and Outlook - GE Healthcare maintains its full-year guidance of 3% to 4% organic sales growth and adjusted EBIT margin expansion of 10 to 40 basis points. - Adjusted EPS guidance remains at $4.80 to $5.00, with expectations for low double-digit growth YoY. - The call did not provide specific updates on the ongoing CFO search or detailed impacts from potential generic competition in the contrast media market.
Bottom line: GE Healthcare demonstrated robust order growth and a solid financial performance in Q2 2026, despite challenges in the PCS segment. The company's focus on innovation and strategic initiatives positions it well for continued growth, making it a compelling investment for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteGE HealthCare — Financial Overview, Stock Price, Market Cap
GE HealthCare is a company. Founded in 1994. As of August 14, 2026, the company's market capitalization is $33329928535 with a current stock price of $73.79.